IDEAYA Biosciences (IDYA) Expected to Announce Earnings on Thursday

IDEAYA Biosciences (NASDAQ:IDYA) will likely be releasing its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect the company to announce earnings of ($1.03) per share and revenue of $5.9460 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, February 20, 2026 at 12:30 PM ET.

IDEAYA Biosciences Trading Up 2.7%

Shares of NASDAQ IDYA opened at $33.25 on Wednesday. The stock has a market cap of $2.92 billion, a P/E ratio of -17.88 and a beta of 0.10. IDEAYA Biosciences has a twelve month low of $13.45 and a twelve month high of $39.28. The stock has a 50 day moving average of $34.72 and a two-hundred day moving average of $30.22.

Wall Street Analysts Forecast Growth

Several analysts recently commented on IDYA shares. JPMorgan Chase & Co. upped their price target on shares of IDEAYA Biosciences from $74.00 to $79.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. New Street Research set a $30.00 target price on shares of IDEAYA Biosciences in a research note on Tuesday, October 21st. Mizuho boosted their price target on IDEAYA Biosciences from $44.00 to $46.00 and gave the company an “outperform” rating in a research report on Tuesday, November 11th. Truist Financial upped their price objective on IDEAYA Biosciences from $59.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Finally, BTIG Research reiterated a “buy” rating and issued a $62.00 target price on shares of IDEAYA Biosciences in a research note on Tuesday, October 21st. Fifteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, IDEAYA Biosciences has an average rating of “Moderate Buy” and a consensus target price of $46.60.

Institutional Trading of IDEAYA Biosciences

A number of institutional investors have recently modified their holdings of the business. Royal Bank of Canada lifted its position in shares of IDEAYA Biosciences by 30.1% during the 1st quarter. Royal Bank of Canada now owns 122,460 shares of the company’s stock valued at $2,006,000 after acquiring an additional 28,322 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in IDEAYA Biosciences by 8.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 57,044 shares of the company’s stock valued at $938,000 after purchasing an additional 4,308 shares in the last quarter. Millennium Management LLC raised its holdings in IDEAYA Biosciences by 345.2% during the first quarter. Millennium Management LLC now owns 547,637 shares of the company’s stock worth $8,970,000 after purchasing an additional 424,625 shares during the last quarter. American Century Companies Inc. boosted its position in IDEAYA Biosciences by 862.7% during the second quarter. American Century Companies Inc. now owns 114,644 shares of the company’s stock worth $2,410,000 after purchasing an additional 102,736 shares in the last quarter. Finally, Norges Bank acquired a new stake in IDEAYA Biosciences in the second quarter valued at $643,000. 98.29% of the stock is currently owned by hedge funds and other institutional investors.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.